TW200640487A - Combination of XOLAIR with immunosuppressive agent - Google Patents

Combination of XOLAIR with immunosuppressive agent

Info

Publication number
TW200640487A
TW200640487A TW095103825A TW95103825A TW200640487A TW 200640487 A TW200640487 A TW 200640487A TW 095103825 A TW095103825 A TW 095103825A TW 95103825 A TW95103825 A TW 95103825A TW 200640487 A TW200640487 A TW 200640487A
Authority
TW
Taiwan
Prior art keywords
immunosuppressive agent
xolair
combination
pharmaceutically acceptable
present
Prior art date
Application number
TW095103825A
Other languages
English (en)
Inventor
Charles Edward Owen
Howard George Fox
Christoph Walker
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TW200640487A publication Critical patent/TW200640487A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW095103825A 2005-02-04 2006-02-03 Combination of XOLAIR with immunosuppressive agent TW200640487A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0502358.5A GB0502358D0 (en) 2005-02-04 2005-02-04 Organic compounds

Publications (1)

Publication Number Publication Date
TW200640487A true TW200640487A (en) 2006-12-01

Family

ID=34355808

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095103825A TW200640487A (en) 2005-02-04 2006-02-03 Combination of XOLAIR with immunosuppressive agent

Country Status (20)

Country Link
US (1) US20080206237A1 (zh)
EP (1) EP1846031A1 (zh)
JP (1) JP2008528650A (zh)
KR (1) KR20070100344A (zh)
CN (1) CN101111265A (zh)
AR (1) AR053541A1 (zh)
AU (1) AU2006210098A1 (zh)
BR (1) BRPI0607349A2 (zh)
CA (1) CA2595976A1 (zh)
GB (1) GB0502358D0 (zh)
GT (1) GT200600023A (zh)
IL (1) IL184713A0 (zh)
MA (1) MA29273B1 (zh)
MX (1) MX2007009436A (zh)
NO (1) NO20074497L (zh)
PE (1) PE20061203A1 (zh)
RU (1) RU2007132980A (zh)
TN (1) TNSN07304A1 (zh)
TW (1) TW200640487A (zh)
WO (1) WO2006082052A1 (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006086361A2 (en) * 2005-02-08 2006-08-17 Novartis Ag ANTILYMPHOCYTE ANTIBODY INDUCTION BY COMBINATION OF AN SlP RECEPTOR AGONIST/MODULATOR AND OF IMMUNOSUPPRESSIVE DRUGS
KR20220162801A (ko) 2008-04-11 2022-12-08 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
ES2742419T3 (es) * 2008-09-17 2020-02-14 Xencor Inc Nuevas composiciones y métodos para tratar trastornos mediados por IgE
JP5843783B2 (ja) * 2009-12-18 2016-01-13 サノフイ ＧＰＶＩに対する新規アンタゴニスト抗体および該抗体のＦａｂフラグメントならびにこれらの使用
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
EP2679681B2 (en) 2011-02-25 2023-11-15 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific FC antibody
AR085749A1 (es) * 2011-04-01 2013-10-23 Novartis Ag Formulaciones
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
KR20180054923A (ko) 2014-12-19 2018-05-24 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
KR102515796B1 (ko) 2014-12-19 2023-03-30 추가이 세이야쿠 가부시키가이샤 항-c5 항체 및 그의 사용 방법
MX2017008978A (es) 2015-02-05 2017-10-25 Chugai Pharmaceutical Co Ltd Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, antiocuerpor de union a interleucina 8 (il-8) y usos de los mismos.
EP4269440A3 (en) 2015-02-27 2024-02-28 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
WO2017106859A1 (en) 2015-12-18 2017-06-22 University Of Notre Dame Du Lac Covalent heterobivalent antibody inhibitors and ligands
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
US11053308B2 (en) 2016-08-05 2021-07-06 Chugai Seiyaku Kabushiki Kaisha Method for treating IL-8-related diseases
WO2018139623A1 (en) 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
DE102017215154A1 (de) 2017-08-30 2019-02-28 Markus Bläss Zusammensetzung zur topischen Behandlung von nicht-Mikroorganismus-verursachten entzündlichen Haut- und Schleimhauterkrankungen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
GB0200429D0 (en) * 2002-01-09 2002-02-27 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CN101111265A (zh) 2008-01-23
EP1846031A1 (en) 2007-10-24
RU2007132980A (ru) 2009-03-10
KR20070100344A (ko) 2007-10-10
NO20074497L (no) 2007-10-26
GT200600023A (es) 2006-08-16
TNSN07304A1 (en) 2008-12-31
IL184713A0 (en) 2007-12-03
BRPI0607349A2 (pt) 2009-09-01
CA2595976A1 (en) 2006-08-10
AU2006210098A1 (en) 2006-08-10
PE20061203A1 (es) 2006-12-19
MA29273B1 (fr) 2008-02-01
JP2008528650A (ja) 2008-07-31
GB0502358D0 (en) 2005-03-16
US20080206237A1 (en) 2008-08-28
WO2006082052A1 (en) 2006-08-10
AR053541A1 (es) 2007-05-09
MX2007009436A (es) 2007-08-17

Similar Documents

Publication Publication Date Title
TW200640487A (en) Combination of XOLAIR with immunosuppressive agent
TW200716552A (en) Novel thiophene derivatives
ZA200807274B (en) Novel pyridine derivatives
RS52169B (en) STABLE LAKVINIMOD PREPARATIONS
MY154909A (en) Novel thiophene derivatives
NO20052285D0 (no) Faste, partikkelformige, antifungale preparater for farmasoytisk anvendelse
WO2004089396A3 (en) Anti-fungal peptidomimetics
TW200744667A (en) Foamable suspension gel
WO2005068503A3 (en) M-csf-specific monoclonal antibody and uses thereof
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
EA200700042A1 (ru) РАСПЫЛЯЕМЫЕ В ВИДЕ АЭРОЗОЛЯ СУСПЕНЗИОННЫЕ КОМПОЗИЦИИ С TG 227ea ИЛИ TG 134a В КАЧЕСТВЕ ПРОПЕЛЛЕНТА
WO2007037849A3 (en) Compositions and methods for the intraocular transport of therapeutic agents
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
MY149306A (en) Solid preparation containing an insulin sensitizer
TW200642689A (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
WO2007016285A3 (en) M-csf specific monoclonal antibody and uses thereof
EP1978034A4 (en) ANTI-PERIOSTINE ANTIBODIES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PERIOSTIN-RELATED DISEASE CONTAINING THE ANTIBODY
EP1731609A4 (en) INHIBITOR OF THE EXPRESSION OF RAD51, MEDICAMENT CONTAINING THE INHIBITOR AS ACTIVE INGREDIENT AND USE THEREOF
WO2008003050A3 (en) Gallium nitrate formulations
MXPA03010054A (es) Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.
UA89408C2 (ru) Твердая фармацевтическая композиция пролонгированного высвобождения 1-(2,3,4-триметоксибензил)пиперазина и способ ее получения
WO2007121471A3 (en) Dialkyl ether delivery agents
WO2006138026A8 (en) Stable pharmaceutical compositions including motilin-like peptides
TW200635934A (en) Amorphous tacrolimus and preparation thereof